| P2093 | author name string | Elizabeth R Gerstner | |
| | K Ina Ly | |
| P2860 | cites work | Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors | Q48457964 |
| | How often are nonenhancing supratentorial gliomas malignant? A population study | Q48481183 |
| | Apparent diffusion coefficients for differentiation of cerebellar tumors in children. | Q48496367 |
| | Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. | Q48506910 |
| | Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques | Q48525569 |
| | Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery | Q48568075 |
| | Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? | Q48586356 |
| | Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? | Q48696807 |
| | Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas | Q48706313 |
| | Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? | Q48778621 |
| | Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma | Q48911908 |
| | Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma | Q48926325 |
| | Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? | Q48939530 |
| | Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. | Q51495475 |
| | Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy | Q51542843 |
| | Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. | Q51825204 |
| | Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. | Q51889688 |
| | Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense? | Q52142783 |
| | Diagnostic performance of apparent diffusion coefficient parameters for glioma grading. | Q52382025 |
| | Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. | Q52584624 |
| | Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. | Q53033649 |
| | MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. | Q53258784 |
| | The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. | Q53604415 |
| | A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. | Q55461252 |
| | Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. | Q55472338 |
| | Angiogenesis | Q56689455 |
| | Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue | Q64004327 |
| | Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma | Q70505985 |
| | Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization | Q73022770 |
| | Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway | Q85648806 |
| | Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach | Q23760721 |
| | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 |
| | An integrated genomic analysis of human glioblastoma multiforme | Q24648860 |
| | Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR | Q24683340 |
| | New PET radiopharmaceuticals beyond FDG for brain tumor imaging | Q26830736 |
| | Somatic mutations associated with MRI-derived volumetric features in glioblastoma | Q28607337 |
| | MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. | Q30413586 |
| | Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study | Q30413713 |
| | Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers | Q30414111 |
| | Normalization of the vasculature for treatment of cancer and other diseases | Q30471456 |
| | Advanced magnetic resonance imaging of the physical processes in human glioblastoma | Q30847284 |
| | Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging | Q30847288 |
| | PET imaging for brain tumor diagnostics | Q30863535 |
| | Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis | Q30873150 |
| | Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response | Q30907831 |
| | Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy | Q30951794 |
| | pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI | Q30976860 |
| | Multiparametric Imaging Analysis: Magnetic Resonance Spectroscopy | Q31136688 |
| | MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy | Q31137181 |
| | Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis | Q33260013 |
| | Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment | Q33475538 |
| | Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma | Q33597353 |
| | Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma | Q33616589 |
| | Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. | Q33744660 |
| | Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T. | Q33762927 |
| | Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma | Q33816600 |
| | Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme | Q33824804 |
| | Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy | Q33838502 |
| | The role of mechanical forces in tumor growth and therapy | Q33942378 |
| | Molecular imaging of gliomas with PET: opportunities and limitations | Q33961188 |
| | Compartment models of the diffusion MR signal in brain white matter: a taxonomy and comparison | Q34048677 |
| | Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy | Q34053028 |
| | Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors | Q34132735 |
| | Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas | Q43274900 |
| | High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging | Q43898278 |
| | Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography | Q43975260 |
| | Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors | Q44263995 |
| | Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging | Q44418561 |
| | Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. | Q44461998 |
| | Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches. | Q45945185 |
| | Identifying spatial imaging biomarkers of glioblastoma multiforme for survival group prediction. | Q45948096 |
| | Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy | Q46094484 |
| | Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. | Q46270281 |
| | Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy | Q46643956 |
| | Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. | Q46902232 |
| | Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. | Q46937729 |
| | Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. | Q47200237 |
| | Differentiation between Radiation Necrosis and Tumor Progression Using Chemical Exchange Saturation Transfer. | Q47352648 |
| | Brain metastases: neuroimaging | Q47879878 |
| | A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images | Q47949037 |
| | Expression of somatostatin receptor subtypes in human brain tumors | Q48017831 |
| | Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and br | Q48130398 |
| | Epidural Metastases From Follicular Thyroid Cancer Mimicking Meningiomas in 68Ga-DOTATATE PET. | Q48155088 |
| | Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. | Q48278725 |
| | 2-[C-11]thymidine imaging of malignant brain tumors. | Q48286386 |
| | Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography | Q48383589 |
| | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas | Q48412951 |
| | Noninvasive detection of glutamate predicts survival in pediatric medulloblastoma | Q34134686 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate | Q34359533 |
| | Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas | Q34369456 |
| | Positron emission tomography image-guided drug delivery: current status and future perspectives | Q34446108 |
| | Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. | Q34722450 |
| | From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? | Q35679377 |
| | Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. | Q35680814 |
| | Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma | Q35771783 |
| | Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics | Q35894329 |
| | Machine Learning methods for Quantitative Radiomic Biomarkers | Q35960448 |
| | Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma | Q36037594 |
| | The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: A meta-analysis | Q36308850 |
| | Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. | Q36367397 |
| | Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. | Q36618214 |
| | 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas | Q36738040 |
| | Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. | Q36759382 |
| | Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy | Q37039043 |
| | Applications and limitations of radiomics | Q37052862 |
| | Molecular imaging with PET. | Q37143447 |
| | Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging | Q37174245 |
| | Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome | Q37492118 |
| | Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients. | Q37496863 |
| | Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. | Q37580469 |
| | Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates | Q37851221 |
| | Pseudoprogression after glioma therapy: a comprehensive review | Q38094809 |
| | Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. | Q38364006 |
| | Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics | Q38926681 |
| | Management of diffuse low-grade gliomas in adults - use of molecular diagnostics | Q39301977 |
| | Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma | Q39685607 |
| | Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. | Q40433973 |
| | Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response | Q40497804 |
| | Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas. | Q41120949 |
| | The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival. | Q41416115 |
| | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties? | Q41527203 |
| | Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade | Q41736519 |
| | Meta-analysis of peritumoural rCBV values derived from dynamic susceptibility contrast imaging in differentiating high-grade gliomas from intracranial metastases. | Q41952383 |
| | Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases | Q42391408 |
| | Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. | Q42702324 |
| | Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors | Q43187131 |
| P433 | issue | 8 | |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 40 | |
| P577 | publication date | 2018-06-21 | |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies | |
| P478 | volume | 19 | |